Website News and Research

RSS

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering and concurrent private placement of its common stock, resulting in net proceeds to Lexicon of approximately $181.4 million after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

20 Mar 2010

CCAGW calls upon Congress to vote against healthcare bill

The Council for Citizens Against Government Waste today called upon Congress to reject any attempts to alter the nation’s healthcare system using parliamentary gimmicks and urged members to vote against the bill.

20 Mar 2010

China Sky One Medical's Myocardial Infarction and Urine Microalbumin Diagnostic Kits receive CE certification

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the receipt of Conformite Europeenne (CE) certification for its Myocardial Infarction and Urine Microalbumin Diagnostic Kits. The CE marking certifies that the two products have met the European Union health and safety standards and are approved for sale in the 27 EU countries and four members of the European Free Trade Association.

20 Mar 2010

Susan G. Komen receives $31,680 as donation for the Cure, San Diego

The Associates of AimLoan.com, a San Diego based Internet Direct Lender, announced a generous donation to Susan G. Komen for the Cure, San Diego for a total of $31,680. This contribution positions the organization as the second largest corporate donor in San Diego. The donation is a result of their 4th Quarter 2009 Community Service Website Campaign.

20 Mar 2010

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

BioDelivery Sciences International, Inc. has filed its Annual Report with the U.S. Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2009. Such Form 10-K is available on the SEC’s website at www.sec.gov.

20 Mar 2010

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. today announced that one abstract has been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL.

19 Mar 2010

Jail and fines for performing circumcision: Massachusetts Judiciary Committee rejects bill

A bill calling for prison time and fines for those who perform circumcision on any male under the age of 18 was rejected by the Judiciary Committee of the Massachusetts state legislature.

19 Mar 2010

Malvern image analysis system measures sub-visible particulates in biotherapeutics

Specialists at Malvern Panalytical have demonstrated the application of dynamic particle image analysis to the measurement of sub-visible particulates in biological therapeutics, using the Sysmex FPIA-3000 particle characterization system.

From Malvern Panalytical 18 Mar 2010

Legacy Biotechnologies commences production of Reme-Flu

Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies’ unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.

18 Mar 2010

Tissue micro-processing solutions at volumes <1mL

At Analytica 2010 in Munich, Germany, Seward Ltd will demonstrate its small tissue processing solutions in Hall B2, Stand 130. This range includes the Stomacher® 80 microbag, designed specifically for use in the Stomacher 80 microBiomaster to prepare and process biological samples at volumes as low as 250µL to 5 mL.

18 Mar 2010

CCAC launches online campaign to raise colorectal screening awareness

As part of its March awareness month kick off, the Colorectal Cancer Association of Canada has launched a unique campaign to encourage Canadian men and women to show their butts online so as to raise awareness about the importance of getting screened for colorectal cancer.

18 Mar 2010

New campaign invites people share their journeys through Ontario's health care system

Ontario's doctors are giving a voice to patients across the province with their latest public awareness campaign. The campaign features real people sharing their journeys through Ontario's health care system and highlights the unique relationship between patients and their doctors.

18 Mar 2010

MediCare International offers insurance for all nationalities

The Lebanon is an important centre for international workers - Post conflict international health cover hard to arrange - Good hospital facilities can only be accessed with the right cover - MediCare International offers insurance for all nationalities

18 Mar 2010

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Toxins released by certain microalgae can contaminate fish and shellfish which then become toxic to humans. Researchers from CNRS and CEA have, for the first time, identified the mechanisms of action of two of these toxins.

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

ICID provides online planning tools to help non-profit organizations develop pandemic flu plans

On the heels of the recent H1N1 pandemic, the International Centre for Infectious Diseases is providing online planning tools to help non-profit organizations develop pandemic flu plans. It is urging vigilance against future waves of the virus, and advises organizations to take action now to plan for events that could threaten the delivery of service to their clients.

17 Mar 2010

IRIS International announces the launch of new and improved corporate website

IRIS International, Inc., a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today the launch of its new and improved corporate website at www.proiris.com, featuring a newly designed homepage and enhanced navigation tools with access to the latest company information.

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Unapproved drugs: National Minority Quality Forum launches new public information campaign

The National Minority Quality Forum (The Forum) is launching a new public information campaign aimed to help educate consumers, physicians, and policymakers about the risks associated with prescribing and taking unapproved drugs that have not been subjected to the rigorous Food and Drug Administration’s (FDA) review and approval process.

17 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

Website News and Research

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

CCAGW calls upon Congress to vote against healthcare bill

China Sky One Medical's Myocardial Infarction and Urine Microalbumin Diagnostic Kits receive CE certification

Susan G. Komen receives $31,680 as donation for the Cure, San Diego

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

Jail and fines for performing circumcision: Massachusetts Judiciary Committee rejects bill

Malvern image analysis system measures sub-visible particulates in biotherapeutics

Legacy Biotechnologies commences production of Reme-Flu

Tissue micro-processing solutions at volumes <1mL

CCAC launches online campaign to raise colorectal screening awareness

New campaign invites people share their journeys through Ontario's health care system

MediCare International offers insurance for all nationalities

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

ICID provides online planning tools to help non-profit organizations develop pandemic flu plans

IRIS International announces the launch of new and improved corporate website

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Unapproved drugs: National Minority Quality Forum launches new public information campaign

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News